J Korean Med Sci.  2004 Jun;19(3):384-389. 10.3346/jkms.2004.19.3.384.

The Effects of Antidepressant Treatment on Serum Cytokines and Nutritional Status in Hemodialysis Patients

  • 1Department of Psychiatry, College of Medicine, Hallym University, Chunchon, Korea. bkson@hallym.ac.kr
  • 2Division of Nephrology, Department of Internal Medicine, College of Medicine, Hallym University, Chunchon, Korea.
  • 3Department of Psychiatry, Catholic University, Daejeon St' Mary Hospital, Daejeon, Korea.
  • 4Department of Psychiatry, Korea University Medical Center, Seoul, Korea.


The aim of this study was to investigate the effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. Twenty-eight hemodialysis patients with a depressed mood were given 20 mg of fluoxetine for 8 weeks. The degree of depressive symptoms, the serum levels of interleukin-1beta, interleukin- 2, interleukin-6, tumor necrosis factor-alpha, c-reactive protein, and markers of nutritional status were assessed at baseline and after treatment. The outcome was assessed in terms of response to treatment (>50% reduction in the score of the Hamilton depression rating scale). Antidepressant treatment decreased the serum level of interleukin- 1 in both response and nonresponse groups, and increased the serum level of interleukin-6 only in the response group. At baseline, the level of interleukin-6 in the response group was lower than in the nonresponse group. Antidepressant treatment also increased fat distribution significantly in the response group which might have slightly improved the nutritional status. This study suggests that antidepressant treatment improve depressive symptoms and may affect immunological functions and nutritional status in chronic hemodialysis patients with depression.


Depression; Antidepressive Agents; Cytokines; Nutritional Status; Renal Dialysis

MeSH Terms

Antidepressive Agents, Second-Generation/*pharmacology
C-Reactive Protein/biosynthesis
Depression/*drug therapy
Electric Impedance
Middle Aged
Renal Dialysis/*methods
Support, Non-U.S. Gov't
Treatment Outcome
Tumor Necrosis Factor/biosynthesis


1. Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients: the role of depression. J Am Soc Nephrol. 1993. 4:12–27.
2. Israel M. Depression in dialysis patients: a review of psychological factors. Can J Psychiatry. 1986. 31:445–451.
3. Levenson JL, Glocheski S. Psychological factors affecting end-stage renal disease. A review. Psychosomatics. 1991. 32:382–389.
4. Sacks CR, Peterson RA, Kimmel PL. Perception of illness and depression in chronic renal disease. Am J Kidney Dis. 1990. 15:31–39.
5. Smith MD, Hong BA, Robson AM. Diagnosis of depression in patients with end-stage renal disease. Comparative analysis. Am J Med. 1985. 79:160–166.
6. Kim DH, Min SK, Han DS. The characteristics of depression in hemodialysis patients and influencing factors. J Korean Neuropsychiatr Assoc. 1994. 33:39–45.
7. Kim DE. Review of psychiatric aspects of hemodialysis. Human Science. 1993. 17:671–683.
8. Lee YK, Son BK. The relationship between therapeutic compliance and emotional variables in the patients on maintenance hemodialysis. J Korean Neuropsychiatr Assoc. 1998. 37:869–877.
9. Lee TB, Han CH, Son BK. The preliminary study of the effects of antidepressant treatment on the depressive symptoms and the nutritional indexes in the patients with chronic renal failure on maintenance hemodialysis. J Korean Neuropsychiatr Assoc. 2000. 39:1102–1110.
10. Anisman H, Ravindran AV, Griffiths J, Merali Z. Interleukin-1 beta production in dysthymia before and after pharmacotherapy. Biol Psychiat. 1999. 46:1649–1655.
11. Anisman H, Ravindran AV, Griffiths J, Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol Psychiatry. 1999. 4:182–188.
12. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, Rubin AL. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998. 32:107–114.
13. Hory B, Racadot E, Saint-Hillier Y, Peters A, Perol C. Soluble interleukin-2 receptors in chronic renal failure. Am J Nephrol. 1991. 11:276–280.
14. Memoli B. Cytokine production in haemodialysis. Blood Purification. 1999. 17:149–158.
15. Panichi V, Migliori M, De Pietro S, Metelli MR, Taccola D, Perez R, Palla R, Rindi P, Cristofani R, Tetta C. Plasma C-reactive protein in hemodialysis patients: a cross-sectional, longitudinal clinical survey. Blood Purif. 2000. 18:30–36.
16. Dantzer R, Aubert A, Bluthe RM, Gheusi G, Cremona S, Laye S, Konsman JP, Parnet P, Kelley KW. Mechanisms of the behavioural effects of cytokines. Adv Exp Med Biol. 1999. 461:83–105.
17. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999. 461:75–81.
18. Kimmel PL, Peterson RA, Weihs KL, Simmens SJ, Boyle DH, Verme D, Umana WO, Veis JH, Alleyne S, Cruz I. Behavioral compliance with dialysis prescription in hemodialysis patients. J Am Soc Nephrol. 1995. 5:1826–1834.
19. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev. 1988. 8:77–100.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960. 23:56–62.
21. Stahl SM. Essential psychopharmacology. 2000. New York: Cambridge University Press.
22. Blumenfield M, Levy NB, Spinowitz B, Charytan C, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RF. Fluoxetine in depressed patients on dialysis. Int J Psychiat Med. 1997. 27:71–80.
23. Levy NB, Blumenfield M, Beasley CM Jr, Dubey AK, Solomon RJ, Todd R, Goodman A, Bergstrom RR. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatry. 1996. 18:8–13.
24. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M. Low-dose fluoxetine therapy for depression. Psychopharmacol Bull. 1988. 24:183–188.
25. Surman O. Massachusetts General Hospital Handbook of General Hospital Psychiatry. 1991. 3rd ed. St. Louis: 401–430.
26. Pereira BJ, Shapiro L, King AJ, Falagas ME, Strom JA, Dinarello CA. Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int. 1994. 45:890–896.
27. Cappelli G, DiFelice A, Perrone S, Ballestri M, Bonucchi D, Savazzi AM, Ciuffreda A, Lusvarghi E. Which level of cytokine production is critical in haemodialysis? Nephrol Dial Transplant. 1998. 13:Suppl 7. 55–60.
28. Jahn B, Betz M, Deppisch R, Janssen O, Hansch GM, Ritz E. Stimulation of beta 2-microglobulin synthesis in lymphocytes after exposure to Cuprophan dialyzer membranes. Kidney Int. 1991. 40:285–290.
29. Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis. 1993. 21:125–137.
30. Parker TF 3rd, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int. 1996. 49:551–556.
31. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol. 1993. 3:1409–1415.
32. Ritz E, Deppisch R, Stier E, Hansch G. Atherogenesis and cardiac death: are they related to dialysis procedure and biocompatibility? Nephrol Dial Transplant. 1994. 9:Suppl 2. 165–172.
33. Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology. 1999. 20:370–379.
34. Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmacher T. Illness, cytokines, and depression. Ann New York Acad Sci. 2000. 917:478–487.
35. Kubera M, Simbirtsev A, Mathison R, Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 2000. 96:255–266.
36. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci. 1997. 247:228–233.
37. Paul WE. Pleiotropy and redundancy: T cell-derived lymphokines in the immune response. Cell. 1989. 57:521–524.
38. Kim YK, Maes M. The role of the cytokine network in psychological stress. Acta Neuropsychiatrica. 2003. 15:148–155.
39. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990. 75:40–47.
40. Kohase M, Henriksen-Destefano D, Sehgal PB, Vilcek J. Dexamethasone inhibits feedback regulation of the mitogenic activity of tumor necrosis factor, interleukin-1, and epidermal growth factor in human fibroblasts. J Cell Physiol. 1987. 132:271–278.
41. Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol. 1990. 10:5736–5746.
42. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Nat Acad Sci USA. 1994. 91:752–756.
43. Miller AH, Pariante CM, Pearce BD. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv Exp Med Biol. 1999. 461:107–116.
44. Kim YK. The role of cytokines in depression and their therapeutic implication. Korean J Psychopharmacol. 2000. 11:304–312.
45. Ravindran AV, Griffiths J, Merali Z, Anisman H. Circulating lymphocyte subsets in major depression and dysthymia with typical or atypical features. Psychosom Med. 1998. 60:283–289.
46. Cho HH, Lee JI, Yoon KW, Lee HW, Kim KD, Kim JS. A study on the nutritional status of chronic renal failure patients in hemodialysis. Korean J Int Med. 1989. 37:657–664.
47. Bergstrom J, Alvestrand A, Furst P. Plasma and muscle free amino acids in maintenance hemodialysis patients without protein malnutrition. Kidney Int. 1990. 38:108–114.
48. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med. 1981. 305:1176–1181.
49. Lazarus JM. Nutrition in hemodialysis patients. Am J Kidney Dis. 1993. 21:99–105.
50. Yoon JW, Koo JR, Kim JC, Chae DW, Rho JW, Son BK. Effects of anti-depression treatment on nutritional status in maintenance hemodialysis patients. J Am Soc Nephrol. 2001. 12:351.
Full Text Links
  • JKMS
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr